Market Overview

UPDATE: Deutsche Bank Ups PT to $45 on Medtronic on Top-Line Beat

Share:
Related MDT
Medtronic Widens MRI-Compatible Portfolio After FDA Approval Of StrataMR Shunt System
Medtronic Gets FDA Approval For Its Visia AF MRI SureScan And Visia AF

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) and raised its price target from $43 to $45.

Deutsche Bank noted, "In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42,65 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Apr 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Mar 2016NomuraInitiates Coverage onBuy
Mar 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!